18 news items
HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Lowers Price Target to $11
RVNC
13 May 24
HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $12 to $11.
Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
RVNC
13 May 24
Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $9 to $8.
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
ACIC
ADMA
AEHL
10 May 24
Hold to Buy and raised its price target from $33 to $46.
Funko Inc
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
AKAM
RVNC
10 May 24
.
Revance Therapeutics shares rose 0.5% to close at $4.29 on Thursday.
These analysts made changes to their price targets on Revance
Piper Sandler Reiterates Overweight on Revance Therapeutics, Lowers Price Target to $11
RVNC
10 May 24
Piper Sandler analyst David Amsellem reiterates Revance Therapeutics (NASDAQ:RVNC) with a Overweight and lowers the price target from $20 to $11.
j604e 2eu8e8o6e
RVNC
10 May 24
Mizuho analyst Vamil Divan maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $9 to $8.
82adm0ivn7fl2 rm8j
RVNC
10 May 24
Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $18 to $12.
a2xl1
ABSI
AMD
BB
9 Apr 24
extension of strategic collaboration with Sanofi to develop novel targeted protein degraders of STAT6.
Taysha Gene Therapies, Inc
pa4v516z fb92odb9g79xtz0no8anptvttnhvl1m6hlssyc2vr
COIN
GDS
LENZ
11 Mar 24
continued strength in Bitcoin. On Friday, Goldman Sachs upgraded the stock from Sell to Neutral and announced a $282 price target
75q3jkgzic3cbf35z4ncodh3c7x4mzqsw1as 8cqr8jweyo
AADI
AIMD
AKRO
4 Mar 24
Ming Hsun Lee maintained Li Auto with a Buy and raised the price target from $57 to $60.
Revance Therapeutics, Inc
q4wm7zmawqx3zg5i01xydokvqrkf73qzobpw14al9han
ACMR
ADSE
BYND
4 Mar 24
and raised the price target from $57 to $60.
Revance Therapeutics, Inc
0vx6qvr7vf8ser6hczmg01eo
RVNC
1 Mar 24
Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and raises the price target from $8 to $9.
0u8ubbbkp8w7rjqqty5hjkur3csl2bzlq1am27dc4ox1
RVNC
29 Feb 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Revance Therapeutics (NASDAQ:RVNC) with a Buy and maintains $12 price target.
i929n7wsrbe83kqdywyzrotjejv6rhec5x5niw703ns
ADIL
AGFY
AI
29 Feb 24
, UBS maintained a Neutral rating on the stock and raised its price target from $38 to $44.
Duolingo, Inc
g5gx 00xaif52q2
AI
CXM
DUOL
29 Feb 24
revenue guidance above estimates. Also, UBS maintained a Neutral rating on the stock and raised its price target from $38 to $44
jujrle3uhsj0ebjm7pynuly
RVNC
29 Feb 24
Piper Sandler analyst David Amsellem maintains Revance Therapeutics (NASDAQ:RVNC) with a Overweight and lowers the price target from $42 to $20.
qcpqcbvlhiexu n2zxeelkxy7phazdra7bxv
RVNC
29 Feb 24
Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $20 to $18.
n8sv8hxeyhrsry2hutkqs606s
RVNC
23 Feb 24
HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $15 to $12.
- Prev
- 1
- Next